Image created with BioRender.com
OH NO OZEMPIC: How GLP-1 RAs May Be Slimming Down Your Oral Health Aug 3, 2025 8 min read Updated: Sep 10, 2025 Sooyun Christina Kim, Amreet Minhas, Beatrice Sixt Project Smile Global August 3, 2025 In recent years, Ozempic, a medication used to treat type 2 diabetes mellitus (T2DM), has increased in popularity (Callaghan et al
Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials
He is also the lead author of The Story of GLP-1: A Historical Journey in the Treatment of Diabetes and Obesity (Elsevier, 2024, with Sten Madsbad, Jens Meldgaard Bruun and Mads Krogsgaard Thomsen)
Whilst preclinical research suggests potential anti-inflammatory properties, no randomised controlled trials demonstrate efficacy in rheumatoid arthritis
Which year does the post's timeline assign to semaglutide's weight-management approval